{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:58:51Z","timestamp":1790665131224,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K24HL175228"],"award-info":[{"award-number":["K24HL175228"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01238-2","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:17:11Z","timestamp":1790662631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-pill combination therapy for blood-pressure lowering: clinical and implementation differences between the United States and Nigeria"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-2519","authenticated-orcid":false,"given":"Mark D.","family":"Huffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-1988","authenticated-orcid":false,"given":"Dike B.","family":"Ojji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"1238_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.","journal-title":"BMJ"},{"key":"1238_CR2","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0140-6736(25)00991-2","volume":"406","author":"N Wang","year":"2025","unstructured":"Wang N, Salam A, Pant R, Kumar A, Dhurjati R, Haghdoost F, et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. Lancet. 2025;406:915\u201325.","journal-title":"Lancet"},{"key":"1238_CR3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1161\/HYPERTENSIONAHA.122.20458","volume":"80","author":"N Wang","year":"2023","unstructured":"Wang N, Harris K, Woodward M, Harrap S, Mancia G, Poulter N, et al. Clinical utility of short-term blood pressure measures to inform long-term blood pressure management. Hypertension. 2023;80:608\u201317.","journal-title":"Hypertension"},{"key":"1238_CR4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, Roth GA, Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990-2022. J Am Coll Cardiol. 2023;82:2350\u2013473.","journal-title":"J Am Coll Cardiol"},{"key":"1238_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u2013980.","journal-title":"Lancet"},{"key":"1238_CR6","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.122.19222","volume":"79","author":"P Muntner","year":"2022","unstructured":"Muntner P, Miles MA, Jaeger BC, Hannon L III, Hardy ST, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971\u201380.","journal-title":"Hypertension"},{"key":"1238_CR7","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1238_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028573","volume":"12","author":"CG Derington","year":"2023","unstructured":"Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, et al. Antihypertensive medication regimens used by US adults with hypertension and the potential for fixed-dose combination products. J Am Heart Assoc. 2023;12:e028573.","journal-title":"J Am Heart Assoc"},{"key":"1238_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(19)31629-0","volume":"394","author":"IJ Benjamin","year":"2019","unstructured":"Benjamin IJ, Kreutz R, Olsen MH, Schutte AE, Lopez-Jaramillo P, Frieden TR, et al. Fixed-dose combination antihypertensive medications. Lancet. 2019;394:637\u20138.","journal-title":"Lancet"},{"key":"1238_CR10","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jch.14009","volume":"22","author":"A Salam","year":"2020","unstructured":"Salam A, Huffman MD, Kanukula R, Prasad EH, Sharma A, Heller DJ, et al. Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769\u201379.","journal-title":"J Clin Hypertens"},{"key":"1238_CR11","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2468-2667(17)30141-X","volume":"2","author":"MW Attaei","year":"2017","unstructured":"Attaei MW, Khatib R, McKee M, Lear S, Dagenais G, Igumbor EU, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health. 2017;2:e411\u2013e419.","journal-title":"Lancet Public Health"},{"key":"1238_CR12","doi-asserted-by":"publisher","first-page":"102412","DOI":"10.1016\/j.jacadv.2025.102412","volume":"5","author":"W Garcia","year":"2026","unstructured":"Garcia W, Aimiosior O, Choudhury SR, Sambo E, Osi K, Beshah SA, et al. Budget impact and investment case for HEARTS hypertension control programs in 4 low- and middle-income countries. JACC Adv. 2026;5:102412.","journal-title":"JACC Adv"},{"key":"1238_CR13","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/jch.13655","volume":"21","author":"TR Frieden","year":"2019","unstructured":"Frieden TR, Varghese CV, Kishore SP, Campbell NRC, Moran AE, Padwal R, et al. Scaling up effective treatment of hypertension\u2014a pathfinder for universal health coverage. J Clin Hypertens. 2019;21:1442\u20139.","journal-title":"J Clin Hypertens"},{"key":"1238_CR14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043\u201352.","journal-title":"Lancet"},{"key":"1238_CR15","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41440-024-01658-y","volume":"47","author":"MD Huffman","year":"2024","unstructured":"Huffman MD, Baldridge AS, Lazar D, Abbas H, Mejia J, Flowers FM, et al. Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. Hypertens Res. 2024;47:1668\u201377.","journal-title":"Hypertens Res"},{"key":"1238_CR16","doi-asserted-by":"publisher","first-page":"e032236","DOI":"10.1161\/JAHA.123.032236","volume":"13","author":"OA Sanuade","year":"2024","unstructured":"Sanuade OA, Jacobson TA, Quintana A, Flowers FM, Abbasi H, Vu MH, et al. Process evaluation of a double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension within a federally qualified health center network (QUARTET USA). J Am Heart Assoc. 2024;13:e032236.","journal-title":"J Am Heart Assoc"},{"key":"1238_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101883","volume":"4","author":"N Wang","year":"2025","unstructured":"Wang N, Rueter P, Salam A, Huffman MD, Atkins E, Ojji D, et al. Low-dose combinations with 3 or 4 blood pressure-lowering medications for the treatment of hypertension. JACC Adv. 2025;4:101883.","journal-title":"JACC Adv"},{"key":"1238_CR18","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1056\/NEJMoa2515043","volume":"394","author":"CS Anderson","year":"2026","unstructured":"Trident Research Group, Anderson CS, Chow CK, de Silva HA, Senanayake B, Wahab K, Al-Shahi Salman R, et al. Three low-dose antihypertensive agents in a single pill after intracerebral hemorrhage. N Engl J Med. 2026;394:1571\u201382.","journal-title":"N Engl J Med"},{"key":"1238_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1001\/jama.2018.10359","volume":"320","author":"R Webster","year":"2018","unstructured":"Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka (TRIUMPH): a randomized clinical trial. JAMA. 2018;320:566\u201379.","journal-title":"JAMA"},{"key":"1238_CR20","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2024.18080","volume":"332","author":"DB Ojji","year":"2024","unstructured":"Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, et al. Low-dose triple-pill vs standard-care protocols for hypertension treatment in Nigeria: a randomized clinical trial. JAMA. 2024;332:1070\u20139.","journal-title":"JAMA"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01238-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01238-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01238-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:17:12Z","timestamp":1790662632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01238-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":20,"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01238-2","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland and Eli Lilly. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize single pill combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. DBO served as a principal investigator of the VERONICA trial, which evaluated a low-dose triple single-pill combination (GMRx2).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}